# Supracondylar Distal Femur Fractures and Abaloparatide

> **NCT04626141** · PHASE4 · WITHDRAWN · sponsor: **Daniel Horwitz**

## Conditions studied

- Femoral Fractures

## Interventions

- **DRUG:** Abaloparatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04626141
- **Lead sponsor:** Daniel Horwitz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to staffing/enrollment related challenges.
- **Last updated:** 2024-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626141, "Supracondylar Distal Femur Fractures and Abaloparatide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04626141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*